Definitive Healthcare Corp. (NASDAQ:DH) Receives $1.47 Consensus Price Target from Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have been given a consensus recommendation of “Reduce” by the ten research firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $1.4714.

A number of brokerages recently weighed in on DH. Wall Street Zen upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. BTIG Research reiterated a “neutral” rating on shares of Definitive Healthcare in a research report on Friday, September 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Monday, August 31st. Morgan Stanley decreased their target price on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. Finally, Bank of America reaffirmed an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research report on Monday, June 29th.

Institutional Trading of Definitive Healthcare

A number of hedge funds have recently bought and sold shares of DH. Pinnacle Associates Ltd. boosted its position in shares of Definitive Healthcare by 100.0% in the fourth quarter. Pinnacle Associates Ltd. now owns 260,012 shares of the company’s stock worth $746,000 after buying an additional 130,012 shares during the period. Corient Private Wealth LP acquired a new position in Definitive Healthcare during the second quarter valued at $378,000. Squarepoint Ops LLC lifted its stake in Definitive Healthcare by 46.5% in the 2nd quarter. Squarepoint Ops LLC now owns 351,575 shares of the company’s stock worth $292,000 after acquiring an additional 111,634 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in Definitive Healthcare in the 4th quarter worth about $144,000. Finally, Flywheel Private Wealth LLC purchased a new stake in Definitive Healthcare in the 1st quarter worth about $83,000. 98.67% of the stock is owned by hedge funds and other institutional investors.

Definitive Healthcare Stock Down 0.7%

DH opened at $0.96 on Tuesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.86 and a current ratio of 1.86. The company has a market capitalization of $102.29 million, a PE ratio of -0.60, a P/E/G ratio of 11.91 and a beta of 1.40. The stock’s fifty day moving average is $0.80 and its 200-day moving average is $0.90. Definitive Healthcare has a one year low of $0.61 and a one year high of $4.35.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Monday, August 10th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.The firm had revenue of $55.20 million for the quarter, compared to analyst estimates of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. On average, equities analysts predict that Definitive Healthcare will post 0.06 EPS for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp. (NASDAQ: DH) provides commercial intelligence and data analytics solutions for the healthcare industry. Its platform is designed to help organizations identify and understand healthcare providers, institutions, markets and patient populations, supporting decisions related to sales, marketing, market access, strategy and business development.

The company’s products and services include healthcare provider and facility data, claims-based insights, organizational and affiliation information, analytics tools, workflow solutions and intelligence related to clinical trials and healthcare markets.